SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives $11.88 Consensus PT from Brokerages

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have been assigned a consensus rating of “Moderate Buy” from the eleven ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $12.00.

Several research analysts recently issued reports on SABS shares. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, June 15th. Citigroup began coverage on SAB Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $11.00 target price on the stock. Barclays began coverage on SAB Biotherapeutics in a research report on Wednesday, June 24th. They set an “overweight” rating and a $13.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SAB Biotherapeutics in a research report on Friday, April 10th. Finally, Rodman & Renshaw reaffirmed a “buy” rating and set a $13.00 target price on shares of SAB Biotherapeutics in a research report on Monday, May 11th.

SAB Biotherapeutics Price Performance

Shares of NASDAQ:SABS opened at $3.80 on Monday. SAB Biotherapeutics has a 52-week low of $1.67 and a 52-week high of $6.60. The stock has a market cap of $290.55 million, a P/E ratio of -1.80 and a beta of 0.54. The business’s 50 day moving average is $3.70 and its 200 day moving average is $3.85. The company has a quick ratio of 11.45, a current ratio of 11.45 and a debt-to-equity ratio of 0.01.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.15). Sell-side analysts predict that SAB Biotherapeutics will post -1.19 EPS for the current year.

Institutional Trading of SAB Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. PNC Financial Services Group Inc. bought a new stake in SAB Biotherapeutics during the 1st quarter valued at $29,000. ADAR1 Capital Management LLC bought a new stake in SAB Biotherapeutics during the 3rd quarter valued at $30,000. Dimensional Fund Advisors LP bought a new stake in SAB Biotherapeutics during the 3rd quarter valued at $32,000. State of Wyoming bought a new stake in SAB Biotherapeutics during the 4th quarter valued at $34,000. Finally, Virtu Financial LLC bought a new stake in SAB Biotherapeutics during the 3rd quarter valued at $40,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.